Skip to Main Content
Imvax
  • About Us
    • Overview
    • Leadership Team
    • Board of Directors
    • Scientific Advisors
  • Our Science
    • Overview
    • Our Goldspire® Platform
    • Advantages
    • Publications
  • Pipeline
    • Overview
    • Imvax Programs
      • IGV-001
      • IHC-001
      • IUC-001
      • ICC-001
      • IEC-001
      • IOC-001
    • Clinical Trials
  • News & Events
  • Patients & Families
    • Glioblastoma
    • Clinical Trials
    • Resources
    • Contact Us
  • Culture & Careers
    • Our People
    • Benefits
    • Career Opportunities

Zilberberg, J., et al.

Zilberberg, J., et al. “Personalized immunotherapeutic platform with evidence of clinical activity in glioblastoma (IGV-001) protects mice against other lethal solid tumor challenges.” Presented at AACR 2022.

601 Walnut Street, Suite 440W, Philadelphia, PA 19106
267-900-4110
contact@imvax.com

  • Careers at Imvax
  • Privacy Policy
  • Terms of Use
  • LinkedIn
  • Twitter
© Copyright 2025 Imvax®, Inc. All rights reserved.